MedTrace Logo

Prevention of HIV/AIDS and STDs in Women Over Fifty

NCT03810170 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 331

Last updated 2023-09-07

No results posted yet for this study

Summary

In response to the increasing rates of HIV/STD infections among women over the age of 50, especially minority women, and in the attempt to reduce HIV/STD risks for over ten million older adult American women who are impacted by gray divorce and at risk for unsafe sex, the investigators will create, test, and commercialize a novel positive psychology-based "SmartWeb" intervention to promote wellbeing, HIV/STD awareness, and safe sex practices among culturally-diverse older divorced or separated women who are dating. This large end-user market for the proposed HIV/STD risk reduction intervention will greatly facilitate commercialization through advertisements, marketing research based on data mining, and in collaboration with manufacturers of condoms, and other large companies offering health products and services to older women.

Conditions

  • Hiv
  • Sexually Transmitted Diseases
  • Aging

Interventions

BEHAVIORAL

safe sex and HIV/STD prevention education via a website

website providing positive psychology-based advice and education for women over the age of 50 who are divorced. embedded in site is safe sex education.

OTHER

written materials on safe sex

2 page written materials on safe sex and HIV/STD prevention education, as well as weekly emails on general women's health topics

Sponsors & Collaborators

  • Environment and Health Group, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-01
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03810170 on ClinicalTrials.gov